The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2025

Filed:

Jan. 15, 2021
Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Yuan Cheng, Newbury Park, CA (US);

Chawita Netirojjanakul, Longmont, CO (US);

Jerry Ryan Holder, Simi Valley, CA (US);

Bin Wu, Thousand Oaks, CA (US);

James R. Falsey, Moorpark, CA (US);

Bradley J. Herberich, Newbury Park, CA (US);

Kelvin Sham, Thousand Oaks, CA (US);

Leslie P. Miranda, Thousand Oaks, CA (US);

Shu-Chen Lu, Thousand Oaks, CA (US);

Murielle M. Venient-Ellison, Thousand Oaks, CA (US);

Shanaka Stanislaus, Thousand Oaks, CA (US);

Junming Yie, Warren, NJ (US);

Jing Xu, Waltham, MA (US);

Assignee:

Amgen Inc., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 39/395 (2006.01); A61P 3/10 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 39/395 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61P 3/10 (2018.01); C07K 16/28 (2013.01); C07K 16/2869 (2013.01); C07K 2317/77 (2013.01);
Abstract

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.


Find Patent Forward Citations

Loading…